Repatha (evolocumab) is an injectable medicine that helps lower levels of low-density lipoprotein cholesterol (LDL), often called “bad” cholesterol. Approved in 2015, Repatha can now be used in adults ...

Amgen’s Repatha was heralded recently in the media, generating headlines like "New Drug Prevents Heart Attacks in High-Risk Patients." But the company's stock then fell. Who should we believe and why?

Intervention/Treatment: The study tests the intervention of Repatha®, a medication used alongside standard care, to assess its impact on reducing cardiovascular risks such as death, myocardial ...

AmgenNow, a direct-to-patient program, launches with Repatha, following positive Phase III Vesalius-CV trial results showing reduced cardiovascular events. Starting October 6, 2025, AmgenNow will be ...

Almost all (95%) Medicare drug plans cover Repatha. This includes standalone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Repatha is a brand ...

THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...

Amgen Inc. (NASDAQ:AMGN) is one of the best growth stocks to buy now. On October 2, Amgen announced that its landmark Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, confirming that ...

Amgen announced the launch of AmgenNow, a new direct-to-patient programme starting with Repatha (evolocumab). This follows landmark results demonstrating Repatha significantly reduced the risk of ...

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $160 billion and strong financial health according to InvestingPro analysis, launched ...

LONDON (Reuters) - Amgen's new injectable cholesterol drug Repatha has been turned down for use on Britain's state health service, underscoring a worldwide debate about the value of such pricey ...